{"pmid":32409436,"title":"Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19.","text":["Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19.","Analyses of COVID-19 patients with preexisting interstitial lung disease (ILD) or pulmonary sarcoidosis is lacking but registries are ongoing. Treatment of COVID-19 for patients with underlying ILD or sarcoidosis may include hospital admission, possible drug treatment, caution with steroids, and avoidance of mechanical ventilation in acute exacerbation of ILD. Patients with COVID-19 respiratory illness are at risk for developing ILD.","Cleve Clin J Med","Southern, Brian","32409436"],"abstract":["Analyses of COVID-19 patients with preexisting interstitial lung disease (ILD) or pulmonary sarcoidosis is lacking but registries are ongoing. Treatment of COVID-19 for patients with underlying ILD or sarcoidosis may include hospital admission, possible drug treatment, caution with steroids, and avoidance of mechanical ventilation in acute exacerbation of ILD. Patients with COVID-19 respiratory illness are at risk for developing ILD."],"journal":"Cleve Clin J Med","authors":["Southern, Brian"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32409436","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3949/ccjm.87a.ccc026","e_drugs":["Steroids"],"topics":["Treatment"],"weight":1,"_version_":1666897319118766081,"score":9.490897,"similar":[{"pmid":32198915,"title":"[When COVID-19 encounters interstitial lung disease: challenges and management].","text":["[When COVID-19 encounters interstitial lung disease: challenges and management].","In December 2019, a new type of coronavirus pneumonia (COVID-19) emerged in Wuhan, Hubei, and spread rapidly to China and over 100 countries around the world. The lung injury and repair caused by COVID-19 has many similarities with the onset and progression of interstitial lung disease (ILD) . Therefore, it is difficult to distinguish between COVID-19 and some types of new-onset ILD or other causes leading to acute exacerbation of ILD. Clinicians need to comprehensively analyze the epidemic history, disease onset characteristics, clinical manifestations, image characteristics, serological andpathogenic microorganism test results to confirm diagnosis. Because of this, the article will discuss the issues related to the differential diagnosis and management of COVID-19 and ILD, and try to provide reasonable suggestions.","Zhonghua Jie He He Hu Xi Za Zhi","Ren, Y H","Wang, S Y","Liu, M","Guo, Y M","Dai, H P","32198915"],"abstract":["In December 2019, a new type of coronavirus pneumonia (COVID-19) emerged in Wuhan, Hubei, and spread rapidly to China and over 100 countries around the world. The lung injury and repair caused by COVID-19 has many similarities with the onset and progression of interstitial lung disease (ILD) . Therefore, it is difficult to distinguish between COVID-19 and some types of new-onset ILD or other causes leading to acute exacerbation of ILD. Clinicians need to comprehensively analyze the epidemic history, disease onset characteristics, clinical manifestations, image characteristics, serological andpathogenic microorganism test results to confirm diagnosis. Because of this, the article will discuss the issues related to the differential diagnosis and management of COVID-19 and ILD, and try to provide reasonable suggestions."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Ren, Y H","Wang, S Y","Liu, M","Guo, Y M","Dai, H P"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198915","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.3760/cma.j.cn112147-20200315-00339","keywords":["covid-19","differential diagnosis","interstitial lung disease"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138490085048321,"score":312.7961},{"pmid":32333929,"pmcid":"PMC7194738","title":"Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic.","text":["Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic.","The 2019 coronavirus disease (COVID-19) pandemic caused by the SARS-CoV-2 virus has affected virtually all aspects of patient care. Healthcare systems around the world are trying to simultaneously treat patients with COVID-19 infection, prepare for its long-term impacts, and manage patients with other acute and chronic diseases. There are multiple ways that the COVID-19 pandemic will directly affect patients with fibrotic interstitial lung disease (ILD), particularly given their common risk factors for poor outcomes. Major issues for patients with ILD will include restricted access to key components of the diagnostic process, new uncertainties in the use of common ILD pharmacotherapies, limited ability to monitor both disease severity and the presence of medication adverse effects, and significantly curtailed research activities. The purpose of this review is to summarize how COVID-19 has impacted key components of the diagnosis and management of fibrotic ILD as well as to provide strategies to mitigate these challenges. We further review major obstacles for researchers and identify priority areas for future ILD research related to COVID-19. Our goals are to provide practical considerations to support the care of patients with ILD during the COVID-19 pandemic and to provide a road map for clinicians caring for these patients during future infectious disease outbreaks.","Chest","Wong, Alyson W","Fidler, Lee","Marcoux, Veronica","Johannson, Kerri A","Assayag, Deborah","Fisher, Jolene H","Hambly, Nathan","Kolb, Martin","Morisset, Julie","Shapera, Shane","Ryerson, Christopher J","32333929"],"abstract":["The 2019 coronavirus disease (COVID-19) pandemic caused by the SARS-CoV-2 virus has affected virtually all aspects of patient care. Healthcare systems around the world are trying to simultaneously treat patients with COVID-19 infection, prepare for its long-term impacts, and manage patients with other acute and chronic diseases. There are multiple ways that the COVID-19 pandemic will directly affect patients with fibrotic interstitial lung disease (ILD), particularly given their common risk factors for poor outcomes. Major issues for patients with ILD will include restricted access to key components of the diagnostic process, new uncertainties in the use of common ILD pharmacotherapies, limited ability to monitor both disease severity and the presence of medication adverse effects, and significantly curtailed research activities. The purpose of this review is to summarize how COVID-19 has impacted key components of the diagnosis and management of fibrotic ILD as well as to provide strategies to mitigate these challenges. We further review major obstacles for researchers and identify priority areas for future ILD research related to COVID-19. Our goals are to provide practical considerations to support the care of patients with ILD during the COVID-19 pandemic and to provide a road map for clinicians caring for these patients during future infectious disease outbreaks."],"journal":"Chest","authors":["Wong, Alyson W","Fidler, Lee","Marcoux, Veronica","Johannson, Kerri A","Assayag, Deborah","Fisher, Jolene H","Hambly, Nathan","Kolb, Martin","Morisset, Julie","Shapera, Shane","Ryerson, Christopher J"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333929","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.chest.2020.04.019","keywords":["coronavirus","diagnosis","interstitial lung disease","treatment"],"topics":["Prevention"],"weight":1,"_version_":1666138493970022400,"score":290.8642},{"pmid":32479979,"title":"Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries.","text":["Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries.","BACKGROUND: Increasing evidence suggests pernio-like lesions are cutaneous manifestations of COVID-19. OBJECTIVE: To describe clinical and pathologic findings of pernio-like lesions in confirmed or suspected COVID-19 cases. METHODS: An international dermatology registry was circulated to healthcare providers worldwide through the American Academy of Dermatology (AAD), International League of Dermatologic Societies (ILDS), and other organizations. RESULTS: We documented 505 patients with dermatologic manifestations associated with COVID-19, including 318 (63%) with pernio-like lesions. Patients with pernio-like lesions were generally young and healthy, with relatively mild COVID-19. Of 318 cases confirmed or suspected as COVID-19 by providers, twenty-three cases (7%) were laboratory-confirmed COVID-19 positive, and 20 others (6%) were close contacts of confirmed COVID-19 cases. Given current testing criteria, many patients lacked COVID-19 testing access. For 55% of patients, pernio-like lesions were their only symptom. In patients with other COVID-19 symptoms, pernio-like lesions typically appeared after other symptoms. Pernio-like lesions lasted a median of 14 days (IQR 10-21). LIMITATIONS: A case series cannot estimate population level incidence or prevalence. Additionally, there may be confirmation bias in reporting. We cannot exclude an epiphenomenon. CONCLUSIONS: Pernio-like skin changes of the feet and hands, without another explanation, may suggest COVID-19 infection and should prompt confirmatory testing.","J Am Acad Dermatol","Freeman, Esther E","McMahon, Devon E","Lipoff, Jules B","Rosenbach, Misha","Kovarik, Carrie","Takeshita, Junko","French, Lars E","Thiers, Bruce H","Hruza, George J","Fox, Lindy P","32479979"],"abstract":["BACKGROUND: Increasing evidence suggests pernio-like lesions are cutaneous manifestations of COVID-19. OBJECTIVE: To describe clinical and pathologic findings of pernio-like lesions in confirmed or suspected COVID-19 cases. METHODS: An international dermatology registry was circulated to healthcare providers worldwide through the American Academy of Dermatology (AAD), International League of Dermatologic Societies (ILDS), and other organizations. RESULTS: We documented 505 patients with dermatologic manifestations associated with COVID-19, including 318 (63%) with pernio-like lesions. Patients with pernio-like lesions were generally young and healthy, with relatively mild COVID-19. Of 318 cases confirmed or suspected as COVID-19 by providers, twenty-three cases (7%) were laboratory-confirmed COVID-19 positive, and 20 others (6%) were close contacts of confirmed COVID-19 cases. Given current testing criteria, many patients lacked COVID-19 testing access. For 55% of patients, pernio-like lesions were their only symptom. In patients with other COVID-19 symptoms, pernio-like lesions typically appeared after other symptoms. Pernio-like lesions lasted a median of 14 days (IQR 10-21). LIMITATIONS: A case series cannot estimate population level incidence or prevalence. Additionally, there may be confirmation bias in reporting. We cannot exclude an epiphenomenon. CONCLUSIONS: Pernio-like skin changes of the feet and hands, without another explanation, may suggest COVID-19 infection and should prompt confirmatory testing."],"journal":"J Am Acad Dermatol","authors":["Freeman, Esther E","McMahon, Devon E","Lipoff, Jules B","Rosenbach, Misha","Kovarik, Carrie","Takeshita, Junko","French, Lars E","Thiers, Bruce H","Hruza, George J","Fox, Lindy P"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479979","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jaad.2020.05.109","keywords":["covid-19","chilblains","dermatology","pernio","public health"],"topics":["Diagnosis"],"weight":1,"_version_":1668437834993762304,"score":138.67818},{"pmid":32330073,"title":"COVID-19 Lung Injury and High Altitude Pulmonary Edema: A False Equation with Dangerous Implications.","text":["COVID-19 Lung Injury and High Altitude Pulmonary Edema: A False Equation with Dangerous Implications.","Amid efforts to care for the large number of patients with COVID-19, there has been considerable speculation about whether the lung injury seen in these patients is different than ARDS from other causes. One idea that has garnered considerable attention, particularly on social media and in free open access medicine is the notion that lung injury due to COVID-19 is more similar to high altitude pulmonary edema (HAPE). Drawing on this concept, it has also been proposed that treatments typically employed in the management of HAPE and other forms of acute altitude illness, pulmonary vasodilators and acetazolamide, should be considered for COVID-19. Despite some similarities in clinical features between the two entities, such as hypoxemia, radiographic opacities and altered lung compliance, the pathophysiological mechanisms of HAPE and lung injury due to COVID-19 are fundamentally different and the entities cannot be viewed as equivalent. While of high utility in the management of HAPE and acute mountain sickness, systemically delivered pulmonary vasodilators and acetazolamide should not be used in the treatment of COVID-19, as they carry the risk of multiple adverse consequences including worsened ventilation-perfusion matching, impaired carbon dioxide transport, systemic hypotension and increased work of breathing.","Ann Am Thorac Soc","Luks, Andrew M","Swenson, Erik R","32330073"],"abstract":["Amid efforts to care for the large number of patients with COVID-19, there has been considerable speculation about whether the lung injury seen in these patients is different than ARDS from other causes. One idea that has garnered considerable attention, particularly on social media and in free open access medicine is the notion that lung injury due to COVID-19 is more similar to high altitude pulmonary edema (HAPE). Drawing on this concept, it has also been proposed that treatments typically employed in the management of HAPE and other forms of acute altitude illness, pulmonary vasodilators and acetazolamide, should be considered for COVID-19. Despite some similarities in clinical features between the two entities, such as hypoxemia, radiographic opacities and altered lung compliance, the pathophysiological mechanisms of HAPE and lung injury due to COVID-19 are fundamentally different and the entities cannot be viewed as equivalent. While of high utility in the management of HAPE and acute mountain sickness, systemically delivered pulmonary vasodilators and acetazolamide should not be used in the treatment of COVID-19, as they carry the risk of multiple adverse consequences including worsened ventilation-perfusion matching, impaired carbon dioxide transport, systemic hypotension and increased work of breathing."],"journal":"Ann Am Thorac Soc","authors":["Luks, Andrew M","Swenson, Erik R"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330073","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1513/AnnalsATS.202004-327FR","locations":["hypoxemia"],"e_drugs":["Acetazolamide","Carbon Dioxide"],"topics":["Treatment"],"weight":1,"_version_":1666138494667325440,"score":82.769485},{"pmid":32319446,"title":"[It's world war at CoViD-19. The first battle on the front of the viral invasion against the exitus for interstitial pneumonia was decisive.]","text":["[It's world war at CoViD-19. The first battle on the front of the viral invasion against the exitus for interstitial pneumonia was decisive.]","An outbreak of a new coronavirus originating from Wuhan (China), responsible for a severe acute respiratory syndrome (SARS), called SARS-CoV-2, is causing a pandemic disease called CoViD-19 (Coronavirus Disease-19), although strict containment measures and restrictions on individual travel have been taken everywhere to hinder the spread of the virus. The clinical spectrum of this infection includes, in order of lesser to greater severity, asymptomatic viremia, paucisymptomatic forms, clinical conditions characterized by respiratory failure that needs mechanical ventilation and support in an intensive care unit, systemic manifestations of infection, septic shock, and multiple organ dysfunction syndromes. There is currently no vaccine to prevent CoViD-19, but the international scientific community is intensely focused on finding a vaccine that will prevent SARS-CoV-2 transmission. In the meanwhile, to prevent hospitals from risking collapse, it is crucial to stratify patients at high risk of poor lung progression, to find effective monitoring strategies, even at home, for the positive patients and/or those highly at risk of positivity of CoViD-19. Starting from the pathogenetic mechanisms involved in the development of this infection up to the clinical characteristics of the infected patients, in this review we tried to focus on the crucial points of the infection in combination with the appropriateness of the medical intervention. We aim to offer indications of therapeutic intervention that are timely and, as far as possible, effective, targeted to the individual patient in relation to age, clinical condition and comorbidities. An early diagnosis associated with an appropriate therapeutic action in the initial stages of the disease can reduce the progression of CoViD-19 towards interstitial pneumonia, thus interfering with the number of transfers to intensive care and lethality of the pandemic in progress.","Recenti Prog Med","Basta, Giuseppina","Del Turco, Serena","Caselli, Chiara","Melani, Luca","Vianello, Annamaria","32319446"],"abstract":["An outbreak of a new coronavirus originating from Wuhan (China), responsible for a severe acute respiratory syndrome (SARS), called SARS-CoV-2, is causing a pandemic disease called CoViD-19 (Coronavirus Disease-19), although strict containment measures and restrictions on individual travel have been taken everywhere to hinder the spread of the virus. The clinical spectrum of this infection includes, in order of lesser to greater severity, asymptomatic viremia, paucisymptomatic forms, clinical conditions characterized by respiratory failure that needs mechanical ventilation and support in an intensive care unit, systemic manifestations of infection, septic shock, and multiple organ dysfunction syndromes. There is currently no vaccine to prevent CoViD-19, but the international scientific community is intensely focused on finding a vaccine that will prevent SARS-CoV-2 transmission. In the meanwhile, to prevent hospitals from risking collapse, it is crucial to stratify patients at high risk of poor lung progression, to find effective monitoring strategies, even at home, for the positive patients and/or those highly at risk of positivity of CoViD-19. Starting from the pathogenetic mechanisms involved in the development of this infection up to the clinical characteristics of the infected patients, in this review we tried to focus on the crucial points of the infection in combination with the appropriateness of the medical intervention. We aim to offer indications of therapeutic intervention that are timely and, as far as possible, effective, targeted to the individual patient in relation to age, clinical condition and comorbidities. An early diagnosis associated with an appropriate therapeutic action in the initial stages of the disease can reduce the progression of CoViD-19 towards interstitial pneumonia, thus interfering with the number of transfers to intensive care and lethality of the pandemic in progress."],"journal":"Recenti Prog Med","authors":["Basta, Giuseppina","Del Turco, Serena","Caselli, Chiara","Melani, Luca","Vianello, Annamaria"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319446","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1701/3347.33187","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138493605117952,"score":81.15985}]}